Summary
77 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 35% a year over the last 3 years.
- Out of every 100 JPY of revenue, 22 JPY is left as net profit.
- It holds more cash than debt: ¥63.8B against ¥8.60B.
- It earns 17 JPY a year on every 100 JPY of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against the industry (Medical - Instruments & Supplies)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 27.9 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 17% a year. For the next fiscal year analysts expect revenue to grow by 12%. Earnings per share grew by 35% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 30 JPY
- Research and development 9.2 JPY
- Sales and administration 30 JPY
- Taxes and other 8.9 JPY
- Net profit 22 JPY
Net profit, industry median (Medical - Instruments & Supplies) 26 JPY
Out of every 100 JPY of revenue, 22 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.45%
- Paid out of profit
- 40%
- Raised in a row
- 4 years
The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 1
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.